BridgeMD
uPAR PET/MRI in glioma
EU CTIS ID: 2024-519723-20-01
What this study is testing
1) uPAR-PET/MR/uPAR-PET/CT with the tracer 68Ga-NOTA-AE105 can be used to: a. Visualize gliomas, where the uptake of 68Ga-NOTA-AE105 correlates directly with uPAR expression, as determined by immunohistochemical analysis of stereotactically obtained tumor biopsies or biopsies taken during surgery. b. Differentiate high-grade gliomas from low-grade gliomas based on differentiated uptake of the tracer due to varying levels of uPAR expression. c. Preoperatively differentiate between glioma progression/recurrence and post-therapeutic effects based on differentiated uptake of the tracer due to varying levels of uPAR expression. 2) uPAR-PET/MR/uPAR-PET/CT with high uptake of the tracer 68Ga-NOTA-AE105 in the brain tumor is associated with shorter survival.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients aged above 18 years old where imaging (brain MRI or CT) indicate suspicion of glioma and who are referred/planned for stereotactic biopsy, surgery, or oncological treatment. Only patients who are able to understand the patient information and provide informed consent will be included.
You likely can't join if
- Pregnancy. Lactation. Claustrophobia. Age > 85 years. Severe obesity (> 140 kg). Known allergy to the tracer 68Ga-NOTA-AE105
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.